We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (5595)12/14/2020 9:51:18 AM
From: richardred1 Recommendation

Recommended By

  Respond to of 6449
The fisherman becomes the fish!

AstraZeneca's $39 Billion Acquisition of Alexion Represents 'Full, Fair Price,' Wedbush Says

MT Newswires – 9:20 AM ET 12/14/2020

From: richardred10/17/2019 7:20:12 AM

of 6027
Alexion Agrees to Acquire Biopharma Firm Achillion in $930 Million Cash Deal
BY MT Newswires
— 1:28 PM ET 10/16/2019

To: richardred who wrote (3894)5/6/2015 9:31:20 AM
From: richardred of 6027
What a premium for a company with no products on the market.

Alexion Pharma to pay $8.4 billion for Synageva BioPharma

Alexion Pharmaceuticals will pay a huge premium to buy fellow rare disease treatment maker Synageva BioPharma in an $8.4-billion deal for a company with no products on the market.

Shares of Synageva more than doubled in value before markets opened Wednesday and after Alexion said it will pay $115 in cash and a portion of its stock for each Synageva share. That puts the total per-share price at about $226, based on the Tuesday closing price of Alexion shares.

That's a premium of about 136 percent to the $95.87 closing price Tuesday of Synageva BioPharma Corp. shares.